AXQ Capital LP Cuts Stake in AbbVie Inc. $ABBV

AXQ Capital LP cut its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 88.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,133 shares of the company’s stock after selling 8,845 shares during the quarter. AXQ Capital LP’s holdings in AbbVie were worth $262,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Evolution Wealth Management Inc. purchased a new position in AbbVie in the 2nd quarter worth $26,000. Spurstone Advisory Services LLC bought a new position in shares of AbbVie during the second quarter valued at about $28,000. Financial Gravity Companies Inc. purchased a new position in shares of AbbVie in the second quarter worth about $36,000. Delos Wealth Advisors LLC bought a new stake in shares of AbbVie in the 2nd quarter valued at about $39,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in AbbVie during the 3rd quarter valued at about $41,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 1.0%

ABBV opened at $224.66 on Friday. The company has a market cap of $397.24 billion, a price-to-earnings ratio of 95.19, a price-to-earnings-growth ratio of 0.79 and a beta of 0.35. The stock has a fifty day simple moving average of $224.26 and a two-hundred day simple moving average of $222.71. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company’s revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. JPMorgan Chase & Co. lifted their price target on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Evercore decreased their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. BMO Capital Markets reiterated an “outperform” rating and set a $258.00 price target on shares of AbbVie in a report on Thursday, January 15th. Royal Bank Of Canada initiated coverage on shares of AbbVie in a report on Tuesday. They issued an “outperform” rating and a $260.00 price target on the stock. Finally, Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $253.15.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.